Emerging Therapeutic Options in Age-Related Macular Degeneration
被引:9
|
作者:
Querques, Giuseppe
论文数: 0引用数: 0
h-index: 0
机构:
Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Serv Ophthalmol, Creteil, France
Univ Vita Salute San Raffaele, San Raffaele Sci Inst, IRCCS, Dept Ophthalmol, Milan, ItalyUniv Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Serv Ophthalmol, Creteil, France
Querques, Giuseppe
[1
,2
]
Capuano, Vittorio
论文数: 0引用数: 0
h-index: 0
机构:
Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Serv Ophthalmol, Creteil, FranceUniv Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Serv Ophthalmol, Creteil, France
Capuano, Vittorio
[1
]
Frascio, Pietro
论文数: 0引用数: 0
h-index: 0
机构:
Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Serv Ophthalmol, Creteil, France
Univ Genoa, Dept Ophthalmol, Genoa, ItalyUniv Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Serv Ophthalmol, Creteil, France
Frascio, Pietro
[1
,3
]
Bandello, Francesco
论文数: 0引用数: 0
h-index: 0
机构:
Univ Vita Salute San Raffaele, San Raffaele Sci Inst, IRCCS, Dept Ophthalmol, Milan, ItalyUniv Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Serv Ophthalmol, Creteil, France
Bandello, Francesco
[2
]
Souied, Eric H.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Serv Ophthalmol, Creteil, FranceUniv Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Serv Ophthalmol, Creteil, France
Souied, Eric H.
[1
]
机构:
[1] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Serv Ophthalmol, Creteil, France
[2] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, IRCCS, Dept Ophthalmol, Milan, Italy
Intravitreal injection of anti-VEGF drugs currently represents the standard of treatment for exudative age-related macular degeneration. Several therapeutic options including steroids, inhibitors of complement factors, anti-platelet-derived growth factor agents, new anti-VEGF drugs, designed ankyrin repeat proteins, sustained drug delivery devices as an alternative to intravitreal injections and encapsulated cell technology are the objects of several studies and trials worldwide in association with anti-VEGF therapy or not. Expectations are that such efforts will help overcome limitations of current therapy with anti-VEGF, extending the duration of effects and hopefully contributing to the regression of neovascular lesions. (C) 2015 S. Karger AG, Basel